National HealthCare Corporation (NHC) Stock Forecast and Price Target (2026)
Last updated November 2026
Short answer
There is no meaningful price-target consensus for National HealthCare Corporation (NHC): too few analysts publish a target on it for an average to mean anything. Thin coverage is normal for smaller and newer companies and says nothing about the business. No analyst publishes estimates on it either. What is left is the latest reported figures, the drivers and the risks below, which you assess yourself. Walnut is not an investment adviser.
Why NHC has no consensus price target
Sell-side coverage follows trading volume and banking relationships, so smaller companies, recent listings, and names outside the major indices often carry little or none. NHC is one of them. It says nothing about the quality of the business, but it does mean there is no informed average to anchor to, and that any single target you find elsewhere is one analyst's model.
Second-quarter GAAP results were flattered by items that do not repeat: an $18.3 million catch-up of management fees recognized when the affiliate acquisition closed, plus mark-to-market gains on the securities portfolio. Adjusted net income of about $27.6 million, up 7.2% year over year, is the cleaner read on operations. At the October 16, 2026 close near $245 the stock trades around 27.5 times trailing earnings and yields about 1.1%, and trailing multiples still predate the July 1 NHI closing, so they describe a rent-paying, debt-free company rather than the property-owning, leveraged one that exists today. Analyst coverage is thin, so Yahoo Finance shows no usable forward consensus.
NHC: the latest reported figures
No analyst publishes estimates on NHC, so these are the most recent figures we hold, as of October 2026. They describe where the company stands, not where it is going.
- Revenue (TTM): ~$1.56B
- Q2 2026 revenue: ~$408M (+8.8% YoY)
- Q2 2026 diluted EPS: ~$2.54 GAAP, ~$1.74 adjusted
- Net income (TTM): ~$140M (~9% profit margin)
- Market cap: ~$3.84B (~$245 per share)
- P/E (TTM): ~27.5x
- Dividend: ~$0.67 quarterly (~1.1% yield)
Is there a 2030 forecast for NHC?
Not a published one. Analyst price targets run to about twelve months, occasionally two years, and the firms covering NHC do not put out a 2030 number. Anything presenting one is extrapolating a growth rate of its own, and a figure produced that way tells you about the assumption chosen, not about the company.
On the figures we hold as of November 2026, NHC trades at about 28.4 times trailing earnings and 476.8 times forward earnings. A forward multiple at or above the trailing one means the market is not pricing in earnings growth over the next year. Keep that in mind before assuming a long-horizon rise.
For a ten-year question, that frame is more useful. A share price is the market’s estimate of future cash flows discounted to today, so the multiple is already a statement about growth. The long-horizon question is whether National HealthCare Corporation can deliver what is priced in, and what would have to change for that to break. Both are answerable from the drivers and risks below. A number for 2030 is not.
What could move NHC from here
In short: the drivers cited most often are Owning the buildings instead of renting them, Tuck-in acquisitions inside the existing footprint, Demographics and a diversified payor mix. The risk cited most often against it is roughly 29% of net patient revenue comes from Medicaid, and the 2025 federal reconciliation law tightens state provider-tax financing beginning in fiscal 2028, which could squeeze the state rates that fund those beds.
Both sides are worked through properly, with the high and low targets used as the bull and bear anchors, on the NHC is it a buy page.
Your questions about National HealthCare Corporation
Ask Walnut's AI anything about NHC and see how it fits what you own.
FAQ
What is the price target for National HealthCare Corporation (NHC)?
+
There is no meaningful consensus price target for NHC, because too few analysts publish on it. Thin coverage is common for smaller and newer companies. Where only one or two analysts cover a stock, an "average target" is really one person's model, so we do not print a number that would imply more agreement than exists. Check your broker's research tab for whatever individual coverage exists.
Why does NHC have no analyst forecast?
+
Sell-side coverage follows trading volume and banking relationships, so small caps, recent listings, and companies outside the major indices often carry little or none. A lack of coverage says nothing about the business itself. It does mean the analysis starts with you, because there is no published model to build on.
What could move NHC?
+
The drivers and the risks are laid out on this page and in more depth on the NHC "is it a buy" page. Without analyst estimates to anchor to, the useful framing is a set of scenarios.
Walnut is informational, not investment advice, and does not publish price targets of its own. The analyst figures on this page come from a November 2026 data pull of published third-party research, are approximate, and change constantly. The share price is the last one Yahoo Finance reported on November 16, 2026, and every percentage against it on this page is measured from that price. Verify current figures with your broker before acting on them.